These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8294765)

  • 1. [A human monoclonal antibody cocktail for experimental mouse infection with clinically isolated strains of Pseudomonas aeruginosa].
    Miura S; Ishibashi Y; Arai T
    Kansenshogaku Zasshi; 1993 Dec; 67(12):1167-71. PubMed ID: 8294765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
    O'Oka H; Chonan E; Mizutani K; Fukuda T; Kuroiwa Y; Ono Y; Shigeta S
    Microbiol Immunol; 1992; 36(12):1305-16. PubMed ID: 1287405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.
    Patel A; DiGiandomenico A; Keller AE; Smith TRF; Park DH; Ramos S; Schultheis K; Elliott STC; Mendoza J; Broderick KE; Wise MC; Yan J; Jiang J; Flingai S; Khan AS; Muthumani K; Humeau L; Cheng LI; Wachter-Rosati L; Stover CK; Sardesai NY; Weiner DB
    Nat Commun; 2017 Sep; 8(1):637. PubMed ID: 28935938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.
    Sawada S; Kawamura T; Masuho Y; Tomibe K
    J Infect Dis; 1985 Nov; 152(5):965-70. PubMed ID: 3930629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice.
    Oishi K; Sonoda F; Miwa H; Tanaka H; Watanabe K; Matsumoto K; Pollack M
    Microbiol Immunol; 1991; 35(12):1131-41. PubMed ID: 1808464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.
    Shime N; Sawa T; Fujimoto J; Faure K; Allmond LR; Karaca T; Swanson BL; Spack EG; Wiener-Kronish JP
    J Immunol; 2001 Nov; 167(10):5880-6. PubMed ID: 11698464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
    Collins MS; Ladehoff DK; Mehton NS; Noonan JS
    FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.
    Hancock RE; Mutharia LM; Mouat EC
    Eur J Clin Microbiol; 1985 Apr; 4(2):224-7. PubMed ID: 2408887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of immunosuppressed mice against infection with pseudomonas aeruginosa by monoclonal antibodies to outer membrane protein OprI.
    Rahner R; Eckhardt A; Duchêne M; Domdey H; von Specht BU
    Infection; 1990; 18(4):242-5. PubMed ID: 2120132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model.
    Barnea Y; Carmeli Y; Gur E; Kuzmenko B; Gat A; Neville LF; Eren R; Dagan S; Navon-Venezia S
    Plast Reconstr Surg; 2006 Jun; 117(7):2284-91. PubMed ID: 16772930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
    Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
    Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
    DiGiandomenico A; Keller AE; Gao C; Rainey GJ; Warrener P; Camara MM; Bonnell J; Fleming R; Bezabeh B; Dimasi N; Sellman BR; Hilliard J; Guenther CM; Datta V; Zhao W; Gao C; Yu XQ; Suzich JA; Stover CK
    Sci Transl Med; 2014 Nov; 6(262):262ra155. PubMed ID: 25391481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
    Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S
    Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.
    Collins MS; Roby RE
    Am J Med; 1984 Mar; 76(3A):168-74. PubMed ID: 6424446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of an IgM human monoclonal antibody against Pseudomonas aeruginosa in nonseptic patients.
    Meng YG; Wong T; Saravolatz LD; Pennington JE
    J Infect Dis; 1993 Mar; 167(3):784-5. PubMed ID: 8440953
    [No Abstract]   [Full Text] [Related]  

  • 18. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis.
    Faezi S; Sattari M; Mahdavi M; Roudkenar MH
    Burns; 2011 Aug; 37(5):865-72. PubMed ID: 21334822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
    Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
    J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.
    Terashima M; Uezumi I; Tomio T; Kato M; Irie K; Okuda T; Yokota S; Noguchi H
    Infect Immun; 1991 Jan; 59(1):1-6. PubMed ID: 1898896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.